Topic: monoclonal antibody
Aridis filed for a $34.5 million IPO as it plans to move its fully human antibodies for hospital-related infections into late-phase clinical trials.
Compass Therapeutics is coming out of stealth with $132 million in series A cash, 15 prospects in preclinical development and a lead oncology asset poised to enter the clinic in 2019.
Otsuka plans to acquire Visterra and its antibody engineering platform for $430 million in cash, as it aims to build out its discovery efforts.
Vaccinex filed a $46 million Nasdaq IPO to support its development of antibodies and conjugates targeting neurodegenerative diseases and cancer.
Syntimmune has named Vertex’s Mario Saltarelli as chief medical officer, following several leadership changes at the company over the past 18 months.
Biogen and Eisai’s phase 2 Alzheimer’s trial has re-emerged, slowing clinical symptom decline and reducing amyloid plaque accumulation in the brain.
Alder BioPharmaceuticals poached Juno’s COO to lead the company, as it preps to submit its migraine treatment for FDA approval and heavy competition.
Just 48 hours after filing a $115 million IPO, Forty Seven unveiled the first data for its CD47 antibody at ASCO, pledging moves into phase 2 studies.
Syngene partnered with Zumutor to screen antigens against Zumutor’s human antibody libraries, to discover antibody clones for additional development.
Early data from Zymeworks showed its lead bispecific antibody hit an overall response rate of 36%, as a single agent for a variety of HER2+ cancers.